Identifying optimal patient subgroups in ovarian cancer for neoadjuvant PARP inhibitor therapy

Evaluating future use of PARP inhibitors in neoadjuvant therapy for ovarian cancerПодробнее

The Therapeutic Potential of Novel PARP Inhibitors in the Clinic for Epithelial Ovarian CancerПодробнее

Personalizing Advanced Ovarian Cancer Treatment With PARP Inhibitors and Novel ApproachesПодробнее

3/26/2021: Upfront Treatment of Advanced Ovarian Cancer; Ay, Now the Plot ThickensПодробнее

Assessing the role of PARP inhibitors and immunotherapy in ovarian cancerПодробнее

Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Optimizing the Use of PARP Inhibitors in Ovarian CancerПодробнее

PARP inhibitors in ovarian cancer: Clinical updates from SGO 2023Подробнее

PARP inhibitors as first-line maintenance therapy in ovarian cancerПодробнее

Expert Views on the Evolving Role of PARP Inhibitors in the Treatment of Ovarian CancerПодробнее

Ovarian Cancer Symposium 2021: Session 4 PARP InhibitorsПодробнее

Dr. O’Malley on the Optimal Use of PARP Inhibitors in Advanced Ovarian CancerПодробнее

Updates in PARP inhibition for ovarian cancerПодробнее

Precision Medicine in Ovarian Cancer With PARP Inhibitor Therapy and Companion DiagnosticsПодробнее

PARP Inhibitor Therapy for Ovarian Cancer: Practical Prescribing and Medication ManagementПодробнее

Overcoming resistance to PARP inhibition in ovarian cancerПодробнее

PARP inhibitor rechallenging in ovarian cancerПодробнее

How to determine best first line treatment for ovarian cancer?Подробнее

The Advanced Ovarian Cancer Treatment Palette: Candid Conversations on PARP InhibitorsПодробнее